US EditionPublished • loading... • Updated
Tranilast for IPF recommended for orphan drug designation in EU
Summary by Pulmonary Fibrosis News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Tranilast for IPF recommended for orphan drug designation in EU
A committee of the European Medicines Agency (EMA) is recommending orphan drug status — a designation that aims to speed therapy development in rare diseases — for tranilast, the active ingredient in NXP002, an inhaled formulation from Nuformix for treating idiopathic pulmonary fibrosis (IPF). A decision by the European Commission, which grants regulatory status in the European Union, is expected within 30 days. NXP002 is a patented formulation …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium